| The entire DSpace / Väitöskirjat ja tutkielmat / Väitöskirjat / Farmasian tiedekunta | 1 / 2023 | 2 / 2023 | 3 / 2023 | 4 / 2023 | 5 / 2023 | 6 / 2023 | 7 / 2023 | 8 / 2023 | 9 / 2023 | 10 / 2023 | 11 / 2023 | 12 / 2023 | Total |
|---|
| "Pitääkö pohtia miksi joku käyttää?" : Unettomuus ja sen hoito : Apteekkifarmaseuttien näkemyksiä, kokemuksia ja käytäntöjä | 44 |
42 |
70 |
70 |
67 |
59 |
29 |
47 |
64 |
60 |
75 |
53 |
680 |
| A Chemical and Ethnopharmacological Study on Phyllanthus emblica L. (Euphorbiaceae) | 2 |
15 |
7 |
11 |
13 |
8 |
6 |
6 |
14 |
7 |
6 |
4 |
99 |
| A Pharmacoepidemiological Study of Medicine Use among Finnish Conscripts | 7 |
1 |
3 |
8 |
5 |
1 |
0 |
2 |
1 |
1 |
1 |
3 |
33 |
| A study on bacteria-targeted screening and in vitro safety assessment of natural products | 2 |
0 |
4 |
2 |
6 |
4 |
1 |
4 |
3 |
4 |
1 |
4 |
35 |
| ABCC2 transporter and α2 adrenoceptors : Identification of novel compounds and their mode of action | 7 |
1 |
2 |
4 |
26 |
7 |
7 |
4 |
2 |
2 |
1 |
2 |
65 |
| Absorption and pharmacokinetic modelling for drug development | 53 |
49 |
56 |
19 |
44 |
29 |
15 |
10 |
22 |
246 |
27 |
20 |
590 |
| Activation of the TrkB Neurotrophin Receptor by Antidepressant Drugs | 3 |
2 |
6 |
11 |
7 |
8 |
0 |
4 |
3 |
5 |
4 |
7 |
60 |
| Activity and Enzyme Kinetics of Human UDP-Glucuronosyltransferases : Studies of Psilocin Glucuronidation and the Effects of Albumin on the Enzyme Kinetic Mechanism | 16 |
34 |
24 |
16 |
17 |
17 |
12 |
7 |
15 |
12 |
7 |
10 |
187 |
| Adaptive Roles of Dissolution Methods in Development of Poorly Soluble Oncology Compounds | 0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Age-appropriate oral pediatric formulations in hospitals : Evaluation of the suitability of printing technologies in meeting patient needs | 25 |
28 |
40 |
25 |
12 |
15 |
7 |
6 |
8 |
8 |
7 |
3 |
184 |
| Alcohol craving after withdrawal in group-housed female mice : the role of neurotrophic factors | 8 |
6 |
8 |
10 |
9 |
8 |
10 |
4 |
3 |
3 |
9 |
1 |
79 |
| Alginate-based microencapsulation and lyophilization of human retinal pigment epithelial cell line (ARPE-19) for cell therapy | 12 |
9 |
3 |
5 |
10 |
10 |
2 |
3 |
3 |
2 |
0 |
2 |
61 |
| Alkaloids of in vitro cultures of Rhazya stricta | 13 |
23 |
19 |
16 |
34 |
33 |
5 |
7 |
5 |
5 |
1 |
0 |
161 |
| Anabolic steroid glucuronides : Enzyme-assisted synthesis and liquid chromatographic-mass spectrometric analysis | 7 |
3 |
2 |
5 |
11 |
7 |
0 |
0 |
3 |
7 |
5 |
5 |
55 |
| Analysis of neurotransmitters, neurosteroids and their metabolites in biological samples | 10 |
23 |
22 |
7 |
21 |
13 |
6 |
3 |
11 |
8 |
5 |
11 |
140 |
| Aqueous-based amylose-rich maize starch solution and dispersion : a study on free films and coatings | 3 |
4 |
7 |
7 |
5 |
2 |
2 |
3 |
6 |
55 |
61 |
3 |
158 |
| Assessment of In-House Natural Product and Synthetic Compound Libraries Based on In vitro Inhibition of Cholinesterases | 6 |
4 |
8 |
6 |
9 |
5 |
3 |
0 |
1 |
3 |
5 |
0 |
50 |
| Atmospheric pressure photoionization-mass spectrometry | 4 |
1 |
7 |
4 |
10 |
5 |
0 |
3 |
2 |
0 |
8 |
39 |
83 |
| Automatable microplate-based in vitro assays for screening intestinal drug transport and metabolism | 8 |
12 |
5 |
7 |
9 |
5 |
3 |
4 |
2 |
2 |
5 |
2 |
64 |
| Automated dose dispensing service for primary care patients and its impact on medication use, quality and safety | 40 |
34 |
32 |
30 |
30 |
9 |
10 |
7 |
42 |
31 |
34 |
18 |
317 |
| Behavioral effects of antidepressant treatments in mice : a focus on BDNF | 9 |
6 |
10 |
10 |
13 |
7 |
3 |
2 |
10 |
5 |
4 |
5 |
84 |
| Biocompatibility and biofunctionalization of mesoporous silicon particles | 11 |
5 |
9 |
10 |
12 |
9 |
2 |
3 |
5 |
3 |
3 |
6 |
78 |
| Biohybrid Cloaked Nanovaccines For Cancer Immunotherapy | 12 |
17 |
13 |
2 |
14 |
12 |
6 |
14 |
7 |
4 |
10 |
4 |
115 |
| Bioinspired matrices for in vitro hepatic differentiation | 29 |
19 |
38 |
32 |
25 |
39 |
23 |
2 |
22 |
25 |
3 |
3 |
260 |
| Biointeraction assessments of lipid membranes in relation to drug action | 4 |
6 |
11 |
20 |
13 |
6 |
5 |
1 |
2 |
6 |
13 |
59 |
146 |
| Biological Screening of Plant Coumarins | 17 |
25 |
32 |
31 |
27 |
15 |
20 |
18 |
14 |
11 |
9 |
9 |
228 |
| Biomedical applications of nanofibrillar cellulose | 17 |
12 |
11 |
18 |
12 |
30 |
2 |
5 |
10 |
9 |
10 |
7 |
143 |
| Biomimetic Interfaces for Surface Sensitive Drug Discovery Techniques | 7 |
1 |
1 |
1 |
5 |
2 |
2 |
3 |
11 |
13 |
4 |
3 |
53 |
| Biomolecular Screening and Characterization of Antimicrobials Acting on Biofilms and Planktonic Bacteria | 13 |
4 |
1 |
4 |
7 |
8 |
3 |
5 |
3 |
5 |
8 |
4 |
65 |
| Biopharmaceutical Evaluation of Microcrystalline Chitosan as Release-Rate-Controlling Hydrophilic Polymer in Granules for Gastro-Retentive Drug Delivery | 11 |
5 |
3 |
8 |
12 |
9 |
1 |
4 |
8 |
3 |
2 |
1 |
67 |
| Biopharmaceutical Evaluation of Orally and Rectally Administered Hard Hydroxypropyl Methylcellulose Capsules | 7 |
6 |
14 |
18 |
17 |
11 |
1 |
4 |
5 |
14 |
18 |
23 |
138 |
| BIOPHOTONICS IN BIOPHARMACEUTICAL APPLICATIONS | 10 |
3 |
7 |
4 |
15 |
9 |
4 |
4 |
5 |
2 |
8 |
5 |
76 |
| Biopolymer-Based Nanoparticles for Drug Delivery | 7 |
9 |
6 |
8 |
10 |
4 |
3 |
2 |
2 |
2 |
3 |
3 |
59 |
| Brain TrkB neurotrophin receptor as a target for antidepressant treatments | 6 |
6 |
8 |
1 |
3 |
1 |
1 |
1 |
4 |
4 |
2 |
2 |
39 |
| Caco-2 cell cultures in the assessment of intestinal absorption : Effects of some co-administered drugs and natural compounds in biological matrices | 10 |
16 |
20 |
5 |
9 |
4 |
5 |
0 |
3 |
2 |
3 |
3 |
80 |
| Cancer vaccines: anti-tumoral t cell therapy on demand | 0 |
0 |
0 |
0 |
0 |
0 |
0 |
141 |
11 |
10 |
9 |
3 |
174 |
| Capillary Electrophoresis- and Microchip-Mass Spectrometry Interfaces and Their Utilization in Bisphosphonate Analysis | 9 |
4 |
0 |
0 |
5 |
4 |
2 |
4 |
2 |
0 |
1 |
1 |
32 |
| Catechol O-Methyltransferase : Glucuronidation of Inhibitors and Methylation of Substrates | 6 |
3 |
8 |
3 |
8 |
13 |
10 |
23 |
7 |
3 |
2 |
4 |
90 |
| Catechol-O-methyltransferase and pain in rodents and humans | 9 |
6 |
11 |
9 |
14 |
12 |
6 |
5 |
3 |
7 |
4 |
3 |
89 |
| CDNF and MANF in an experimental model of Parkinson's disease in rats | 3 |
1 |
5 |
5 |
5 |
5 |
6 |
3 |
5 |
5 |
3 |
5 |
51 |
| CDNF in an experimental model of Parkinson's disease : studies on gene therapy and protein infusion | 12 |
7 |
5 |
7 |
26 |
13 |
5 |
7 |
16 |
4 |
16 |
11 |
129 |
| Cell encapsulation in hydrogels for long-term protein delivery and tissue engineering applications | 8 |
5 |
4 |
16 |
9 |
6 |
2 |
1 |
5 |
2 |
3 |
2 |
63 |
| Cell-based bioluminescent high-throughput screening methods in antibacterial drug discovery | 6 |
2 |
3 |
2 |
9 |
3 |
4 |
2 |
1 |
0 |
2 |
1 |
35 |
| Centrifugal Granulating Process for Preparing Drug-Layered Pellets Based on Microcrystalline Cellulose Beads | 8 |
3 |
10 |
3 |
11 |
8 |
10 |
6 |
8 |
6 |
7 |
6 |
86 |
| Characterisation and processing of amorphous binary mixtures with low glass transition temperature | 6 |
10 |
5 |
8 |
8 |
5 |
5 |
3 |
2 |
1 |
5 |
4 |
62 |
| Characterization of Ion-Exchange Fibers for Controlled Drug Delivery | 7 |
5 |
2 |
5 |
7 |
11 |
9 |
8 |
6 |
7 |
2 |
4 |
73 |
| Chemical surface modification of porous silicon nanoparticles for cancer therapy | 7 |
8 |
9 |
15 |
9 |
9 |
4 |
22 |
193 |
5 |
3 |
5 |
289 |
| Chronic Myeloid Leukemia Patients' Adherence to Tyrosine Kinase Inhibitors in Finland : A Journey of Eighty-six Patients | 9 |
4 |
1 |
7 |
13 |
4 |
7 |
8 |
15 |
17 |
12 |
8 |
105 |
| Community Pharmacies and the Needs of Mobile EU Citizens : A study on Finns living in Spain | 7 |
4 |
2 |
5 |
5 |
3 |
2 |
1 |
1 |
2 |
2 |
1 |
35 |
| Community Pharmacists’ Contribution to Prospective Medication Risk Management for Older Adults in the Context of Network Theory | 51 |
59 |
45 |
30 |
37 |
16 |
18 |
39 |
17 |
12 |
17 |
11 |
352 |
| Comparison of disaccharides and polyalcohols as stabilizers in freeze-dried protein formulations | 15 |
9 |
18 |
10 |
16 |
12 |
13 |
3 |
12 |
13 |
15 |
8 |
144 |
| Comprehensive Exploration of Bacterial Biofilm Responses to Chemical, Physicochemical and Biological Factors | 0 |
0 |
0 |
0 |
0 |
54 |
8 |
5 |
14 |
11 |
13 |
2 |
107 |
| Compression Behaviour and Enteric Film Coating Properties of Cellulose Esters | 6 |
3 |
3 |
6 |
10 |
6 |
2 |
3 |
3 |
4 |
0 |
2 |
48 |
| Computational analysis of orexin receptors and their interactions with natural and synthetic ligands | 10 |
4 |
11 |
1 |
10 |
8 |
4 |
1 |
1 |
3 |
5 |
4 |
62 |
| Computational studies on membrane proteins and membrane-drug interactions | 4 |
0 |
5 |
2 |
8 |
3 |
5 |
2 |
3 |
1 |
0 |
0 |
33 |
| Computer-assisted separation and primary screening of bioactive compounds | 0 |
2 |
1 |
2 |
5 |
1 |
1 |
3 |
4 |
0 |
2 |
0 |
21 |
| Contributions of µ- and κ-opioidergic systems to ethanol intake and addiction | 6 |
6 |
9 |
3 |
7 |
2 |
1 |
15 |
7 |
1 |
0 |
1 |
58 |
| Controlled Transdermal Drug Delivery by Iontophoresis and Ion-exchange Fiber | 2 |
4 |
2 |
2 |
5 |
1 |
1 |
1 |
1 |
1 |
1 |
0 |
21 |
| Costs, effectiveness and cost-effectiveness of biological drugs in the treatment of rheumatoid arthritis and inflammatory bowel diseases | 6 |
12 |
21 |
7 |
8 |
6 |
5 |
8 |
6 |
3 |
9 |
9 |
100 |
| Crystallization as a Tool for Controlling and Designing Properties of Pharmaceutical Solids | 14 |
14 |
25 |
18 |
16 |
13 |
2 |
8 |
2 |
2 |
2 |
5 |
121 |
| Cytotoxic and apoptotic effects of selected phenolic compounds and extracts from edible plants | 6 |
6 |
9 |
4 |
8 |
1 |
1 |
0 |
3 |
4 |
1 |
2 |
45 |
| Delivery of biologics to the retinal pigment epithelium | 4 |
0 |
2 |
2 |
6 |
2 |
3 |
3 |
4 |
6 |
1 |
3 |
36 |
| Deregulation of Nicotine Replacement Therapy Products in Finland : Reasons for Pharmaceutical Policy Changes and Reflections on Smoking Cessation Practices | 20 |
17 |
50 |
9 |
14 |
9 |
4 |
4 |
8 |
10 |
19 |
12 |
176 |
| Design and synthesis of membrane-bound pyrophosphatase inhibitors against pathogenic protozoan parasites | 19 |
10 |
17 |
9 |
13 |
8 |
5 |
7 |
19 |
3 |
14 |
1 |
125 |
| Desorption ionization mass spectrometry : tools for rapid bio- and pharmaceutical analysis | 3 |
1 |
2 |
4 |
6 |
6 |
4 |
2 |
1 |
2 |
2 |
4 |
37 |
| Developing Safe Medication Practices within a Regional Health Care District in Finland | 34 |
17 |
17 |
21 |
10 |
13 |
3 |
7 |
21 |
13 |
12 |
34 |
202 |
| Development and Application of Comprehensive Medication Review Procedure to Community-Dwelling Elderly | 74 |
29 |
24 |
20 |
19 |
16 |
10 |
11 |
8 |
7 |
6 |
6 |
230 |
| Development and biological characterization of novel ligands for protein-protein interaction-based effects of prolyl oligopeptidase | 14 |
7 |
14 |
22 |
26 |
5 |
4 |
4 |
4 |
3 |
3 |
3 |
109 |
| Development and biopharmaceutical evaluation of press-coated tablets taking account of circadian rhythms of disease | 4 |
9 |
3 |
5 |
5 |
1 |
4 |
2 |
3 |
2 |
0 |
2 |
40 |
| Development and Characterization of Conductive Drug-loaded Scaffolds for Tissue Engineering Applications | 4 |
11 |
5 |
6 |
13 |
9 |
3 |
6 |
3 |
12 |
11 |
4 |
87 |
| Development and optimisation of tools for preclinical studies on Parkinson's disease | 13 |
5 |
10 |
9 |
10 |
9 |
3 |
9 |
6 |
8 |
5 |
2 |
89 |
| Development and Validation of a Drug-Related Problem Risk Assessment Tool for Use by Practical Nurses Working with Community-Dwelling Aged | 38 |
18 |
23 |
26 |
23 |
34 |
22 |
34 |
35 |
28 |
10 |
14 |
305 |
| Development of a Novel Multichamber Microscale Fluid Bed with In-line Near Infrared Spectroscopy and Non-invasive Electrostatic Measurement | 10 |
8 |
2 |
4 |
5 |
4 |
2 |
2 |
3 |
1 |
4 |
3 |
48 |
| Development of Analytical Tools for the Quantification of MANF and CDNF in Disease and Therapy | 5 |
2 |
5 |
2 |
10 |
3 |
1 |
3 |
2 |
2 |
3 |
2 |
40 |
| Development of Computational Methods to Predict Protein Pocket Druggability and Profile Ligands using Structural Data | 4 |
1 |
0 |
4 |
8 |
10 |
3 |
2 |
3 |
1 |
3 |
1 |
40 |
| Development of drug-loaded acetalated dextran-based nanoparticles for hear targeting and treatment of myocardial infarction | 30 |
33 |
20 |
15 |
11 |
20 |
13 |
14 |
17 |
20 |
24 |
22 |
239 |
| Development of in vitro co-culture models and characterization of biofilm inhibitors for bio-fabrication of medical devices and drug discovery applications | 10 |
1 |
4 |
4 |
5 |
8 |
3 |
2 |
2 |
5 |
1 |
2 |
47 |
| Development of infrared laser ablation based ambient mass spectrometry imaging methods | 25 |
13 |
12 |
8 |
14 |
8 |
11 |
4 |
9 |
8 |
11 |
5 |
128 |
| Development of Integrated Databases and Web Resources for drug discovery | 146 |
38 |
38 |
27 |
23 |
17 |
9 |
7 |
3 |
1 |
6 |
10 |
325 |
| Development of Lignin-based Nanoparticles for Cancer Therapy | 20 |
28 |
31 |
20 |
26 |
15 |
0 |
6 |
1 |
8 |
7 |
7 |
169 |
| Development of Mass Spectrometric Methods for Analysis of Anabolic Androgenic Steroids | 22 |
19 |
13 |
16 |
30 |
31 |
5 |
22 |
19 |
20 |
11 |
25 |
233 |
| Development of Multiple-Unit Oral Formulations for Colon-Specific Drug Delivery Using Enteric Polymers and Organic Acids as Excipients | 7 |
4 |
2 |
1 |
10 |
6 |
1 |
2 |
4 |
2 |
1 |
1 |
41 |
| Development of novel vaccine platforms for the treatment of cancer | 13 |
4 |
13 |
9 |
17 |
11 |
1 |
1 |
6 |
3 |
6 |
3 |
87 |
| Development of organotypic liver cell cultures in three-dimensional biomaterial hydrogels | 25 |
22 |
24 |
37 |
31 |
40 |
23 |
1 |
2 |
3 |
2 |
1 |
211 |
| Development of Peptide and Protein Microparticles for Diabetes Therapy : From Fabrication to In Vivo Evaluation | 0 |
0 |
14 |
17 |
12 |
16 |
17 |
6 |
10 |
26 |
23 |
18 |
159 |
| Development of Transformable Nanotherapeutics for Cancer Therapy | 5 |
6 |
6 |
7 |
7 |
5 |
2 |
12 |
5 |
2 |
3 |
4 |
64 |
| Diastereomeric Drug Glucuronides : Enzymatic Glucuronidation and Analysis by Capillary Electrophoresis and Liquid Chromatography-Mass Spectrometry | 8 |
5 |
14 |
7 |
6 |
10 |
8 |
2 |
1 |
1 |
3 |
2 |
67 |
| Different responses of the nigrostriatal and mesolimbic dopaminergic pathways to nicotinic receptor agonists | 4 |
1 |
7 |
3 |
9 |
2 |
4 |
3 |
8 |
4 |
4 |
1 |
50 |
| Digital microfluidics for drug metabolism research in droplet-scale | 7 |
5 |
6 |
5 |
14 |
7 |
5 |
10 |
14 |
5 |
10 |
8 |
96 |
| Direct open air surface sampling/ionization mass spectrometry methods in the study of neutral and nonpolar compounds | 22 |
3 |
5 |
3 |
5 |
4 |
6 |
1 |
2 |
3 |
1 |
0 |
55 |
| Discovery of cardioprotective isoxazole-amide compounds targeting the synergy of transcription factors GATA4 and NKX2-5 | 6 |
0 |
6 |
10 |
12 |
6 |
0 |
5 |
3 |
5 |
2 |
7 |
62 |
| Discovery of OX1 and OX2 orexin receptor ligands | 11 |
5 |
5 |
5 |
10 |
10 |
2 |
3 |
2 |
18 |
8 |
9 |
88 |
| Distribution, regulation and physiological roles of catechol-O-methyltransferase (COMT) in rodents | 4 |
5 |
14 |
4 |
11 |
10 |
8 |
5 |
3 |
1 |
2 |
1 |
68 |
| Dracocephalum moldavica L. and Melissa officinalis L. : Chemistry and Bioactivities Relevant in Alzheimer’s Disease Therapy | 10 |
5 |
2 |
8 |
10 |
14 |
0 |
1 |
2 |
1 |
3 |
5 |
61 |
| Drug Discovery Screening and the Application of Genomics and Proteomics in the Drug Development Process for Chlamydia pneumoniae | 10 |
6 |
0 |
5 |
4 |
5 |
2 |
4 |
3 |
3 |
5 |
2 |
49 |
| Effect of Nicotine on Dopaminergic Neurotransmission and Expression of Fos Protein | 6 |
5 |
4 |
2 |
2 |
2 |
1 |
2 |
3 |
1 |
6 |
1 |
35 |
| Effect of Surface Chemistry on the Immune Responses and Cellular Interactions of Porous Silicon Nanoparticles | 16 |
10 |
2 |
7 |
7 |
9 |
4 |
3 |
2 |
4 |
1 |
3 |
68 |
| Effects of CDNF in experimental models of Huntington´s disease | 5 |
4 |
6 |
9 |
4 |
23 |
0 |
16 |
6 |
22 |
10 |
6 |
111 |
| Effects of chronic nicotine on behavioural and neurochemical responses to morphine | 8 |
5 |
1 |
2 |
8 |
3 |
2 |
3 |
20 |
3 |
1 |
2 |
58 |
| Effects of Opioids on Neuronal Nicotinic Acetylcholine Receptors | 11 |
15 |
13 |
40 |
47 |
36 |
6 |
4 |
5 |
12 |
7 |
3 |
199 |
| Efficacy, Safety and Clinical Outcomes of Biologic Drugs in the Treatment of Rheumatoid Arthritis | 11 |
5 |
11 |
5 |
8 |
9 |
0 |
1 |
8 |
1 |
3 |
4 |
66 |
| Endogenous GDNF as a regulator of midbrain dopamine neurons | 9 |
5 |
9 |
5 |
16 |
11 |
5 |
6 |
18 |
7 |
10 |
4 |
105 |
| Enhancing oncolytic adenovirus therapy by simultaneously activating multiple immune effector populations | 0 |
0 |
0 |
0 |
0 |
20 |
40 |
14 |
9 |
6 |
6 |
5 |
100 |
| Entacapone, A Drug for Parkinson's Disease : A Pharmacokinetic and Pharmacodynamic Study of Entacapone | 6 |
7 |
0 |
12 |
17 |
2 |
0 |
3 |
4 |
5 |
7 |
5 |
68 |
| Evaluating mechanical properties and tabletability of pharmaceutical powders with a novel gravitation-based high-velocity compaction method | 19 |
36 |
45 |
16 |
20 |
7 |
15 |
5 |
26 |
14 |
31 |
21 |
255 |
| Evaluation of natural products in apoptosis, protein kinase C activation and Caco-2 Cell permeability | 6 |
5 |
4 |
2 |
3 |
5 |
2 |
3 |
1 |
0 |
0 |
1 |
32 |
| Evaluation of the Medicinal Uses and Antimicrobial Activity of Piper guineense Schumach &Thonn | 3 |
2 |
2 |
8 |
7 |
3 |
45 |
1 |
3 |
3 |
15 |
0 |
92 |
| Expanding the diversity of solid-state forms of weak bases by applying salt-cocrystal continuum concept : from Polymorphs and Solvates to Salts and Cocrystals | 4 |
4 |
6 |
10 |
6 |
4 |
2 |
1 |
2 |
1 |
2 |
0 |
42 |
| Experimental Neurotrophic Therapies of Parkinson’s Disease : Effects on Nigrostriatal Dopamine System | 7 |
4 |
13 |
12 |
8 |
6 |
3 |
5 |
5 |
4 |
4 |
4 |
75 |
| External signal-activated liposomal drug delivery systems | 12 |
5 |
8 |
6 |
9 |
5 |
2 |
3 |
3 |
2 |
3 |
2 |
60 |
| Extracellular Vesicles : Prospects in Prostate Cancer Biomarker Discovery and Drug Delivery | 1 |
19 |
2 |
6 |
20 |
4 |
4 |
3 |
3 |
1 |
3 |
3 |
69 |
| Extraction and Planar Chromatographic Separation Techniques in the Analysis of Natural Products | 11 |
6 |
10 |
16 |
16 |
8 |
4 |
4 |
4 |
7 |
5 |
6 |
97 |
| Factors Affecting the Tone of the Bovine Retractor Penis Muscle with Special Reference to Endothelins | 6 |
3 |
3 |
4 |
8 |
13 |
3 |
4 |
2 |
2 |
4 |
2 |
54 |
| Field-based Proteochemometric Models Derived from 3D Protein Structures : A Novel Approach to Visualize Affinity and Selectivity Features | 1 |
1 |
17 |
14 |
7 |
3 |
3 |
3 |
3 |
11 |
6 |
1 |
70 |
| Fighting Bugs by Numbers : Bioinformatics Tools for Antimicrobial Drug Discovery | 12 |
3 |
3 |
1 |
7 |
7 |
4 |
4 |
1 |
4 |
2 |
2 |
50 |
| Formulation studies for eliminating saliva carcinogenic acetaldehyde with L-cysteine containing chewing gum | 6 |
6 |
4 |
15 |
10 |
2 |
8 |
7 |
2 |
2 |
2 |
5 |
69 |
| Freeze-drying of nanofibrillated cellulose hydrogel and cells for pharmaceutical applications | 45 |
24 |
32 |
36 |
65 |
40 |
19 |
24 |
16 |
28 |
12 |
15 |
356 |
| From Molecules and Crystals to Solid Dosage Forms : Supramolecular Approach to Understanding Properties and Performance of Pharmaceutical Materials | 0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| From Paper to Cyber : Medicines Information as a Strategic Goal in Finland and the European Union | 31 |
33 |
45 |
21 |
27 |
21 |
5 |
17 |
14 |
15 |
10 |
7 |
246 |
| From Polymorph Screening to Dissolution Testing : Solid Phase Analysis during Pharmaceutical Development and Manufacturing | 7 |
3 |
4 |
9 |
8 |
16 |
4 |
6 |
5 |
12 |
5 |
0 |
79 |
| GDNF and Neurturin isoforms in an experimental model of Parkinson's disease | 5 |
6 |
8 |
4 |
9 |
5 |
4 |
5 |
7 |
3 |
3 |
2 |
61 |
| GDNF/RET signalling in regulation of brain dopaminergic systems : significance for drug addiction | 2 |
2 |
5 |
2 |
3 |
2 |
1 |
3 |
1 |
4 |
2 |
2 |
29 |
| Glial Cell Line-derived Neurotrophic Factor, Neurturin and their Receptors in the Development, Maintenance and Plasticity of the Nervous System | 6 |
3 |
4 |
4 |
7 |
3 |
1 |
1 |
3 |
2 |
2 |
6 |
42 |
| Glucuronidation activity of individual UDP-glucuronosyltransferases : Comparison of activity and substrate specificity among recombinant human UGT enzymes and differences between dog and human subfamily 1A UGT enzymes | 7 |
13 |
17 |
10 |
9 |
6 |
1 |
2 |
2 |
2 |
3 |
0 |
72 |
| Glucuronide Isomers : Synthesis, Structural Characterization, and UDP-glucuronosyltransferase Screening | 18 |
17 |
41 |
25 |
27 |
20 |
11 |
6 |
7 |
7 |
4 |
4 |
187 |
| Granulation in Miniaturised Fluid Bed Using Electrostatic Atomisation | 17 |
6 |
23 |
31 |
24 |
10 |
11 |
18 |
2 |
2 |
2 |
3 |
149 |
| Health from Herbs? Antioxidant Studies on Selected Lamiaceae Herbs in vitro and in Humans | 11 |
1 |
13 |
7 |
16 |
8 |
2 |
2 |
4 |
1 |
5 |
6 |
76 |
| Heated Nebulizer Microchips for Mass Spectrometry | 18 |
12 |
16 |
8 |
15 |
16 |
0 |
6 |
6 |
4 |
8 |
3 |
112 |
| Human Efflux Transporters in Drug Disposition : in vitro Transport of Glucuronide Metabolites | 6 |
6 |
6 |
7 |
7 |
8 |
0 |
4 |
7 |
3 |
8 |
5 |
67 |
| Hydrolysis of tinidazole : Analytical methods and degradation kinetics | 19 |
27 |
16 |
22 |
25 |
29 |
17 |
21 |
19 |
34 |
10 |
10 |
249 |
| Imitation of biologically relevant oxidation reactions by titanium dioxide photocatalysis : Advances in understanding the mimicking of drug metabolism and the oxidation of phosphopeptides | 8 |
2 |
5 |
1 |
9 |
6 |
2 |
5 |
3 |
3 |
1 |
2 |
47 |
| Immobilized enzyme microreactors in drug metabolism research | 18 |
42 |
16 |
13 |
20 |
11 |
6 |
4 |
8 |
3 |
6 |
1 |
148 |
| Immunological boosting and personalization of oncolytic virotherapies for cancer treatment | 10 |
7 |
11 |
3 |
13 |
9 |
3 |
6 |
3 |
0 |
2 |
0 |
67 |
| Immunomodulatory approaches after experimental ischemic stroke | 8 |
5 |
11 |
6 |
8 |
11 |
0 |
5 |
1 |
3 |
2 |
5 |
65 |
| Immunotoxicological effects induced by engineered nanomaterials | 5 |
2 |
4 |
0 |
4 |
2 |
0 |
2 |
1 |
1 |
0 |
0 |
21 |
| Implementation of the principles of patient counselling into practice in Finnish community pharmacies | 8 |
23 |
25 |
16 |
11 |
12 |
5 |
9 |
11 |
8 |
10 |
3 |
141 |
| Importance of COMT in the regulation of prefrontal dopamine | 6 |
2 |
8 |
5 |
9 |
4 |
4 |
2 |
2 |
55 |
7 |
11 |
115 |
| Improving the Palatability of Minitablets for Feline Medication | 12 |
10 |
12 |
18 |
44 |
12 |
3 |
115 |
8 |
3 |
30 |
4 |
271 |
| In vitro evaluation of the pharmacokinetic effects of BCRP interactions | 5 |
4 |
4 |
3 |
13 |
5 |
0 |
5 |
3 |
6 |
5 |
6 |
59 |
| In vitro, in vivo, and in silico investigations of polymer and lipid based nanocarriers for drug and gene delivery | 10 |
5 |
8 |
10 |
13 |
11 |
8 |
4 |
4 |
8 |
2 |
1 |
84 |
| Increasing process understanding of wet granulation by spectroscopic methods and dimension reduction tools | 2 |
5 |
10 |
10 |
9 |
6 |
1 |
4 |
0 |
2 |
13 |
5 |
67 |
| Information Technology Development Needs in Community Pharmacies : A Strategic Approach | 32 |
34 |
31 |
32 |
27 |
27 |
13 |
4 |
7 |
15 |
21 |
6 |
249 |
| Insights into particle formation and analysis | 6 |
2 |
11 |
8 |
4 |
4 |
5 |
1 |
0 |
1 |
2 |
0 |
44 |
| Interactions of natural products with β-lactoglobulins, members of the lipocalin family | 6 |
6 |
2 |
2 |
8 |
1 |
2 |
3 |
2 |
1 |
1 |
2 |
36 |
| Interfacial Phenomena in Pharmaceutical Low Moisture Content Powder Processing | 6 |
4 |
3 |
3 |
5 |
6 |
2 |
1 |
5 |
4 |
10 |
4 |
53 |
| Investigating physical properties of solid dosage forms during pharmaceutical processing : Process analytical applications of vibrational spectroscopy | 2 |
2 |
5 |
23 |
24 |
7 |
0 |
5 |
4 |
4 |
2 |
0 |
78 |
| Investigation of Bacterial Biofilms on Clinically Relevant Materials and Effects of Antimicrobials | 9 |
8 |
10 |
20 |
13 |
5 |
4 |
9 |
5 |
7 |
4 |
1 |
95 |
| Ion mobility based separation techniques for the direct analysis of gaseous and solid samples and fundamental studies of gas phase reactions | 6 |
4 |
7 |
6 |
11 |
3 |
4 |
3 |
1 |
27 |
5 |
3 |
80 |
| Is the door closed? : In vitro studies on the pharmacokinetic effects of OATP1B1 gene-drug and drug-drug interactions. | 110 |
67 |
34 |
13 |
7 |
7 |
9 |
9 |
5 |
2 |
14 |
6 |
283 |
| Iäkkäiden omahoidon tukeminen moniammatillisesti perusterveydenhuollossa : Lääkehoidon kokonaisarvioinnin sisältävän ihmiskeskeisen omahoitomallin kehittäminen ja arviointi | 28 |
39 |
74 |
59 |
68 |
29 |
3 |
10 |
24 |
28 |
32 |
17 |
411 |
| Launching New Products in the Finnish Pharmaceutical Industry : A Relationship Approach | 17 |
7 |
14 |
20 |
34 |
14 |
17 |
13 |
10 |
6 |
4 |
2 |
158 |
| Learning from Medication Errors in Healthcare : How to Make Medication Error Reporting Systems Work? | 26 |
41 |
36 |
48 |
40 |
23 |
26 |
11 |
32 |
42 |
41 |
26 |
392 |
| Lebanese Plants and Plant-Derived Compounds Against Colon Cancer | 6 |
4 |
1 |
2 |
15 |
4 |
2 |
2 |
2 |
1 |
0 |
7 |
46 |
| Liposomal Drug Delivery : Light Triggered Drug Release and Targeting to the Posterior Segment of the Eye | 17 |
7 |
4 |
19 |
16 |
7 |
1 |
3 |
6 |
6 |
3 |
3 |
92 |
| Liquid chromatography and atmospheric pressure ionisation mass spectrometry in the analysis of drug seizures | 3 |
10 |
8 |
6 |
14 |
5 |
2 |
2 |
2 |
2 |
1 |
3 |
58 |
| Liquid Chromatography-Mass Spectrometry in Studies of Drug Metabolism and Permeability | 18 |
11 |
13 |
9 |
17 |
11 |
6 |
10 |
14 |
8 |
11 |
9 |
137 |
| Liquid Chromatography-Tandem Mass Spectrometry in Studies of Neurotransmitters and Their Metabolites in the Brain | 15 |
11 |
12 |
14 |
13 |
10 |
10 |
17 |
24 |
17 |
2 |
8 |
153 |
| Liquid Chromatography-Tandem Mass Spectrometry in Studies of Steroid Hormones and Steroid Glucuronide Conjugates in Brain and Urine | 10 |
16 |
14 |
12 |
24 |
8 |
13 |
12 |
2 |
10 |
6 |
4 |
131 |
| Liquid Chromatography− and Capillary Electrophoresis−Mass Spectrometry in Glucuronide Analysis | 7 |
3 |
2 |
2 |
11 |
17 |
0 |
4 |
4 |
4 |
3 |
0 |
57 |
| Long-Term Oral Nicotine Treatment and Daily Variations in Brain Monoamines and Motor Activity | 7 |
2 |
4 |
3 |
3 |
3 |
1 |
1 |
4 |
1 |
3 |
2 |
34 |
| Lääkkeiden turvallisen käyttökuntoon saattamisen edistäminen sairaaloiden osastoilla | 107 |
83 |
108 |
79 |
89 |
40 |
30 |
69 |
102 |
77 |
152 |
83 |
1019 |
| Lääkkeisiin ja lääkkeen kaltaisiin tuotteisiin liittyvät toiveet ja illuusiot : psykodynaaminen näkökulma | 26 |
25 |
32 |
28 |
27 |
20 |
5 |
15 |
20 |
12 |
17 |
24 |
251 |
| Machine Vision for Enhanced Understanding of Solid-State Impact on Solubility of Drug Compounds | 5 |
7 |
12 |
5 |
18 |
8 |
4 |
13 |
3 |
14 |
7 |
5 |
101 |
| Mass spectrometry-based applications and analytical method development for metabolomics | 12 |
9 |
15 |
15 |
16 |
4 |
4 |
5 |
6 |
6 |
6 |
2 |
100 |
| Mast cells and synovial fibroblasts as novel targets for antirheumatic therapy | 8 |
5 |
4 |
3 |
5 |
2 |
2 |
0 |
3 |
4 |
2 |
2 |
40 |
| Mechanisms of nanoparticle formation and gene delivery of polyplex-based delivery systems | 10 |
7 |
11 |
5 |
12 |
13 |
2 |
7 |
8 |
0 |
2 |
1 |
78 |
| Mechanistic Studies of Drug Dissolution Testing : Implications of solid phase properties and in vivo prognostic media | 12 |
7 |
1 |
4 |
7 |
9 |
2 |
20 |
13 |
5 |
8 |
6 |
94 |
| Medication safety in intravenous drug administration : error causes and systemic defenses in hospital setting | 45 |
59 |
69 |
55 |
56 |
27 |
18 |
31 |
48 |
41 |
24 |
15 |
488 |
| Medication Use in Elite Athletes | 3 |
6 |
3 |
9 |
12 |
4 |
4 |
3 |
5 |
2 |
18 |
4 |
73 |
| Medicines information sources and services for consumers : A special focus on the Internet and people with depression | 43 |
38 |
25 |
31 |
44 |
29 |
14 |
15 |
28 |
16 |
18 |
10 |
311 |
| Mesenchymal stromal cells and nanofibrillar cellulose for wound healing therapy | 15 |
4 |
8 |
6 |
7 |
12 |
3 |
6 |
1 |
6 |
7 |
11 |
86 |
| Mesoporous silica- and silicon-based materials as carriers for poorly water soluble drugs | 21 |
17 |
14 |
19 |
27 |
19 |
6 |
8 |
17 |
9 |
4 |
4 |
165 |
| Mesoporous silicon systems for oral protein/peptide-based diabetes mellitus therapy | 5 |
3 |
0 |
3 |
3 |
6 |
5 |
2 |
5 |
1 |
4 |
4 |
41 |
| Method development for the analysis of steroids, vitamin D and oxysterols | 5 |
4 |
3 |
3 |
9 |
2 |
1 |
4 |
3 |
0 |
0 |
2 |
36 |
| Microchip Atmospheric Pressure Ionization-Mass Spectrometry | 6 |
8 |
8 |
2 |
4 |
4 |
2 |
3 |
3 |
1 |
1 |
4 |
46 |
| Microchip technology in mass spectrometry-based bioanalysis : Advances in the analysis of peptides, proteins, and pharmaceuticals | 8 |
4 |
14 |
7 |
12 |
3 |
7 |
6 |
2 |
18 |
11 |
2 |
94 |
| Microfabrication of Organically Modified Ceramics for Bio-MEMS | 7 |
14 |
16 |
12 |
20 |
14 |
7 |
5 |
6 |
8 |
12 |
11 |
132 |
| Microfluidics and Nanotechnology in Pharmaceutical Analysis and Drug Metabolism Research | 5 |
14 |
21 |
8 |
7 |
2 |
6 |
5 |
3 |
3 |
5 |
3 |
82 |
| Micropillar Array Based Microchips for Electrospray Ionization Mass Spectrometry, Microreactors, and Liquid Chromatographic Separation | 12 |
4 |
4 |
2 |
15 |
79 |
9 |
0 |
4 |
4 |
5 |
3 |
141 |
| Miniaturization of Drug Solubility and Dissolution Testings | 10 |
14 |
11 |
24 |
18 |
18 |
4 |
7 |
7 |
2 |
2 |
3 |
120 |
| Miniaturized Devices for Reaction Monitoring Using Online Mass Spectrometry and Developments Towards Reaction Control | 10 |
2 |
6 |
8 |
6 |
2 |
3 |
1 |
1 |
3 |
1 |
0 |
43 |
| Modelling alpha-synuclein-based Parkinson's disease and studies with CDNF | 16 |
11 |
7 |
26 |
22 |
33 |
7 |
18 |
22 |
25 |
13 |
10 |
210 |
| Modelling and simulation approaches for waiving in vivo pharmacokinetic formulation studies | 1 |
2 |
10 |
9 |
11 |
4 |
3 |
4 |
8 |
2 |
4 |
4 |
62 |
| Modern analytical approaches to pharmaceutical powder characterisation and processing | 16 |
11 |
12 |
10 |
12 |
12 |
4 |
7 |
2 |
6 |
6 |
2 |
100 |
| Modifications and carriers for improved oligonucleotide delivery : Synthesis, analysis and biological testing | 14 |
15 |
3 |
1 |
15 |
10 |
6 |
9 |
8 |
2 |
3 |
5 |
91 |
| Modulation of Brain Dopaminergic Neurotransmission in Alcohol-Preferring Rats by Alcohol and Opioids | 5 |
0 |
4 |
2 |
2 |
2 |
1 |
1 |
2 |
1 |
1 |
4 |
25 |
| Molecular dynamics simulations of drug delivery liposomes and their interactions with bloodstream elements | 24 |
17 |
24 |
12 |
37 |
54 |
14 |
7 |
9 |
113 |
76 |
20 |
407 |
| Molecular Dynamics Simulations of the Lipid Environment in Protein Kinase C Targeting | 0 |
0 |
0 |
0 |
137 |
27 |
5 |
10 |
5 |
7 |
5 |
8 |
204 |
| Molecular evolution of G protein-coupled receptors : insights into the orexin system | 11 |
6 |
9 |
8 |
16 |
13 |
7 |
5 |
5 |
4 |
11 |
14 |
109 |
| Multi-Approach Design and Fabrication of Hybrid Composites for Drug Delivery and Cancer Therapy | 21 |
4 |
2 |
3 |
11 |
9 |
2 |
5 |
2 |
1 |
4 |
1 |
65 |
| Multifunctional Nanoparticles for Targeted Drug Delivery and Imaging for Ischemic Myocardial Injury | 13 |
15 |
3 |
9 |
11 |
12 |
13 |
11 |
7 |
18 |
18 |
2 |
132 |
| Multifunctional Porous Silicon Based Nanocomposites for Cancer Targeting and Drug Delivery | 18 |
3 |
10 |
7 |
8 |
4 |
0 |
5 |
4 |
4 |
1 |
5 |
69 |
| N-Glucuronidation of Drugs and Other Xenobiotics | 15 |
9 |
14 |
35 |
28 |
8 |
12 |
33 |
37 |
52 |
25 |
17 |
285 |
| Nanocellulose as a delivery platform for pharmaceuticals and nanoparticles | 26 |
20 |
18 |
7 |
13 |
9 |
6 |
10 |
4 |
9 |
1 |
16 |
139 |
| Nanocrystal formulation for poorly soluble drugs | 41 |
30 |
37 |
41 |
54 |
15 |
8 |
16 |
10 |
17 |
14 |
10 |
293 |
| Nanocrystals for Drug Delivery Applications | 13 |
4 |
5 |
7 |
11 |
6 |
5 |
1 |
3 |
2 |
0 |
57 |
114 |
| Nanofibrillar cellulose for encapsulation and release of pharmaceuticals | 16 |
11 |
17 |
14 |
13 |
10 |
4 |
2 |
7 |
8 |
2 |
6 |
110 |
| Nanofibrillar cellulose in drug delivery | 52 |
40 |
51 |
65 |
63 |
62 |
41 |
13 |
22 |
8 |
7 |
10 |
434 |
| Natural Products as a Source for Rational Antichlamydial Lead-Discovery | 6 |
4 |
8 |
5 |
6 |
5 |
6 |
2 |
4 |
1 |
2 |
6 |
55 |
| Near Infrared spectroscopy, a quality control tool for the different steps in the manufacture of herbal medicinal products | 2 |
3 |
14 |
3 |
7 |
8 |
23 |
48 |
9 |
5 |
2 |
10 |
134 |
| Near-Infrared Reflectance Spectroscopy in the Measurement of Water as a Part of Multivariate Process Monitoring of Fluidised Bed Granulation Process | 26 |
7 |
5 |
8 |
18 |
4 |
3 |
6 |
0 |
2 |
2 |
7 |
88 |
| Neonatal Fc Receptor-Targeted Nanoparticles for Oral Delivery of Anti-Diabetic Drugs | 10 |
13 |
7 |
6 |
9 |
18 |
2 |
4 |
2 |
9 |
8 |
6 |
94 |
| Neuro- and immunotoxic effects of fumonisin B1 in cells | 2 |
2 |
1 |
1 |
2 |
5 |
8 |
0 |
3 |
1 |
2 |
1 |
28 |
| Neurobiology of gambling disorder and alcohol use disorder comorbidity : preclinical study | 15 |
30 |
30 |
8 |
9 |
6 |
6 |
11 |
8 |
2 |
7 |
3 |
135 |
| Neutron Activation-Based Gamma Scintigraphic Imaging and Scintigraphy-Based Pharmacokinetic Modelling of Per Oral Controlled Release Drug Delivery | 14 |
3 |
4 |
11 |
4 |
4 |
1 |
6 |
1 |
0 |
1 |
1 |
50 |
| New approaches for the identification of antivirulence agents based on LsrK inhibition : from assay development to screening campaigns | 2 |
3 |
3 |
3 |
11 |
6 |
3 |
8 |
0 |
2 |
6 |
3 |
50 |
| New insights into crystallization of amorphous materials | 22 |
6 |
11 |
7 |
7 |
8 |
3 |
1 |
0 |
3 |
3 |
1 |
72 |
| New Insights into the Amorphous State and Related Solid-State Transformations | 10 |
4 |
2 |
5 |
7 |
3 |
2 |
3 |
1 |
1 |
1 |
2 |
41 |
| New insights to the brain functions of prolyl oligopeptidase | 8 |
0 |
8 |
2 |
5 |
6 |
2 |
1 |
6 |
4 |
3 |
4 |
49 |
| New Methods to Evaluate Applicability of Powders and Granules for Tablet Compression | 31 |
15 |
26 |
6 |
10 |
12 |
5 |
6 |
7 |
12 |
27 |
11 |
168 |
| Nicotinic acetylcholine receptors in experimental models of Parkinson’s disease and levodopa-induced dyskinesia : focus on α5 subunit-containing receptors | 12 |
5 |
13 |
27 |
24 |
15 |
34 |
57 |
7 |
4 |
5 |
12 |
215 |
| Non-invasive analysis of liposome protein corona structure and composition in a single label-free workflow | 6 |
3 |
8 |
12 |
13 |
15 |
17 |
13 |
9 |
18 |
10 |
1 |
125 |
| Non-labelled surface sensitive techniques as platforms for pharmaceutical nanotechnology research | 14 |
3 |
1 |
8 |
7 |
9 |
2 |
4 |
3 |
5 |
2 |
0 |
58 |
| Non-linear Label-free Optical Imaging of Cells, Nanocrystal Cellular Uptake and Solid-State Analysis in Pharmaceutics | 7 |
2 |
4 |
2 |
15 |
3 |
2 |
4 |
2 |
5 |
5 |
10 |
61 |
| Novel Mass Spectrometric Analysis Methods for Anabolic Androgenic Steroids in Sports Drug Testing | 8 |
9 |
29 |
2 |
8 |
8 |
1 |
2 |
2 |
0 |
1 |
4 |
74 |
| Novel neurotrophic treatments in rats and toxin sensitivity of genetically modified mice in the unilateral 6 OHDA model of Parkinson's disease | 1 |
3 |
5 |
6 |
4 |
4 |
4 |
3 |
3 |
3 |
1 |
4 |
41 |
| Observational studies on skin cancer risk : focus on genetics, alcohol and phototoxic medicines | 7 |
4 |
3 |
11 |
14 |
4 |
4 |
4 |
10 |
3 |
3 |
0 |
67 |
| Ocular and systemic pharmacokinetic models for drug discovery and development | 7 |
18 |
5 |
7 |
11 |
3 |
3 |
4 |
2 |
2 |
6 |
7 |
75 |
| Ocular Pharmacokinetic Effects of Drug Binding to Melanin Pigment and the Vitreous Humor | 18 |
20 |
31 |
29 |
35 |
43 |
26 |
5 |
10 |
12 |
8 |
19 |
256 |
| Opening new perspectives for visual characterisation of pharmaceutical solids | 11 |
7 |
3 |
3 |
8 |
5 |
1 |
3 |
1 |
0 |
0 |
0 |
42 |
| Oxidative stress and XIAP signalling in neuronal cells | 8 |
2 |
5 |
11 |
12 |
5 |
30 |
87 |
4 |
2 |
2 |
1 |
169 |
| Particle Size Determination during Fluid Bed Granulation : Tools for Enhanced Process Understanding | 3 |
3 |
9 |
24 |
16 |
17 |
19 |
23 |
13 |
1 |
4 |
2 |
134 |
| Pharmacological and toxicological characterisation of GATA4- and protein kinase C-targeted compounds in cardiac cell models | 12 |
2 |
10 |
16 |
16 |
9 |
13 |
16 |
2 |
8 |
1 |
3 |
108 |
| Plant secondary metabolites in Peucedanum palustre and Angelica archangelica and their plant cell cultures | 13 |
9 |
17 |
25 |
28 |
18 |
11 |
7 |
7 |
3 |
8 |
2 |
148 |
| Polyphenolic and essential oil composition of Mentha and their antimicrobial effect | 21 |
24 |
19 |
26 |
40 |
23 |
12 |
13 |
35 |
42 |
61 |
18 |
334 |
| Porous Silicon-Based Multicomposites for Controlled Drug Delivery | 8 |
6 |
3 |
8 |
11 |
6 |
12 |
5 |
7 |
6 |
3 |
4 |
79 |
| Porous Silicon-Based On-Demand Nanohybrids for Biomedical Applications | 10 |
9 |
11 |
6 |
9 |
6 |
1 |
3 |
2 |
2 |
11 |
16 |
86 |
| Potential of Automatic Substitution of Biologics to Enhance Rational Use of Medicines in Finland | 0 |
218 |
64 |
38 |
33 |
24 |
9 |
32 |
42 |
28 |
22 |
16 |
526 |
| Preparation and characterization of extracellular vesicles for cancer therapy | 11 |
4 |
11 |
2 |
2 |
2 |
2 |
4 |
1 |
4 |
7 |
5 |
55 |
| Preparation and Characterization of Poly(Lactic Acid) Nanoparticles for Pharmaceutical Use | 21 |
29 |
23 |
14 |
15 |
7 |
4 |
5 |
0 |
2 |
4 |
4 |
128 |
| Preparation, Analysis and Cholesterol Lowering Effect of a Novel Microcrystalline Beta-Sitosterol Suspension in Oil and Phase Behaviour of Beta-Sitosterol with Cholesterol | 1 |
2 |
4 |
2 |
11 |
2 |
4 |
2 |
6 |
2 |
2 |
1 |
39 |
| Process Analytical Technology Approach on Fluid Bed Granulation and Drying : Identifying Critical Relationships and Constructing the Design Space | 42 |
35 |
52 |
65 |
76 |
87 |
47 |
91 |
32 |
44 |
38 |
26 |
635 |
| Profiling Antichlamydial Compounds in Monocyte and Macrophage Cell Models | 5 |
6 |
3 |
1 |
11 |
7 |
4 |
4 |
1 |
7 |
4 |
1 |
54 |
| Prolyl oligopeptidase and alpha-synuclein in the regulation of nigrostriatal dopaminergic neurotransmission | 4 |
6 |
5 |
6 |
23 |
5 |
10 |
21 |
5 |
6 |
8 |
5 |
104 |
| Prospective medication risk management in primary care : Enhancing coordination of care and community pharmacists' participation | 17 |
58 |
33 |
27 |
27 |
7 |
5 |
11 |
13 |
12 |
8 |
3 |
221 |
| Protein Kinase C Activators as Anticancer Agents : Compound Development and Pharmacological Characterisation | 11 |
4 |
13 |
14 |
13 |
4 |
5 |
4 |
9 |
5 |
4 |
3 |
89 |
| Protein Kinase C and Anaplastic Lymphoma Kinase Targeted Compounds | 9 |
6 |
7 |
4 |
9 |
9 |
2 |
1 |
5 |
5 |
8 |
6 |
71 |
| Proteomics in Preclinical Drug Discovery and Development | 8 |
3 |
6 |
1 |
6 |
1 |
1 |
2 |
3 |
6 |
5 |
1 |
43 |
| Pseudopeptides and Peptidomimetics Modulating the Proteolytic Activity of Kallikrein-related Peptidase 3 | 7 |
6 |
10 |
6 |
8 |
4 |
4 |
6 |
4 |
9 |
6 |
5 |
75 |
| Public Health and Patient Care Aspects in Pharmacy Education and Pharmacists’ Role in National Public Health Programs in India | 18 |
26 |
22 |
14 |
26 |
9 |
3 |
2 |
7 |
6 |
4 |
1 |
138 |
| Purification of pharmaceuticals and nutraceutical compounds by sub- and supercritical extraction and chromatography | 6 |
7 |
2 |
7 |
8 |
3 |
1 |
0 |
3 |
3 |
3 |
3 |
46 |
| Putative neuroprotective compounds in in vitro models of dopaminergic neurodegeneration | 15 |
14 |
4 |
6 |
8 |
2 |
2 |
1 |
1 |
0 |
3 |
1 |
57 |
| Raman Spectroscopy and Surface Plasmon Resonance as Photonic Tools for Biopharmaceutical Applications | 4 |
3 |
5 |
12 |
17 |
4 |
0 |
5 |
3 |
2 |
2 |
1 |
58 |
| Rapid Prototyping of Polymer-Based Organ-on-a-Chip Devices : The Impact of Materials on Cell Proliferation | 14 |
13 |
9 |
40 |
6 |
8 |
4 |
3 |
1 |
2 |
4 |
5 |
109 |
| Rapid-acting antidepressants : Shared neuropharmacological mechanisms | 7 |
24 |
26 |
9 |
34 |
13 |
2 |
1 |
10 |
8 |
7 |
3 |
144 |
| Rejuvenating the brain’s endogenous regenerative potential : focus on the role of MANF in brain development and ischemic brain injury | 5 |
13 |
6 |
2 |
7 |
5 |
1 |
0 |
0 |
1 |
3 |
1 |
44 |
| Replacement of Dietary Fats : Effects on Serum Lipids and Plasma Fatty Acid Composition with Special Emphasis on the Metabolism of Essential Fatty Acids | 3 |
4 |
0 |
2 |
8 |
5 |
0 |
1 |
5 |
1 |
1 |
1 |
31 |
| Rheological properties and the state of water of microcrystalline cellulose and silicified microcrystalline cellulose wet masses | 10 |
1 |
3 |
4 |
8 |
3 |
4 |
2 |
1 |
0 |
2 |
2 |
40 |
| Rheological properties of pharmaceutical creams containing sorbitan fatty acid ester surfactants | 17 |
4 |
4 |
4 |
8 |
5 |
4 |
3 |
4 |
7 |
8 |
12 |
80 |
| Role of brain dopamine in psychomotor stimulation induced by morphine and cocaine in alcohol-preferring and alcohol-avoiding rats | 10 |
3 |
1 |
5 |
7 |
2 |
0 |
2 |
0 |
0 |
1 |
4 |
35 |
| Role of Cerebral Dopamine and Noradrenaline in Locomotor Sensitization to Morphine in Mice | 4 |
2 |
3 |
3 |
3 |
2 |
0 |
0 |
2 |
1 |
5 |
1 |
26 |
| Role of Excipients in Moisture Sorption and Physical Stability of Solid Pharmaceutical Formulations | 12 |
8 |
18 |
4 |
22 |
13 |
22 |
46 |
10 |
12 |
31 |
87 |
285 |
| Role of nicotinic acetylcholine receptors in cerebral dopaminergic transmission and expression of fos protein | 7 |
4 |
2 |
5 |
4 |
1 |
0 |
1 |
5 |
2 |
2 |
2 |
35 |
| Role of Ret Signaling in the Regulation of the Nigrostriatal Dopaminergic System in Mice | 3 |
3 |
6 |
8 |
4 |
10 |
8 |
1 |
3 |
7 |
4 |
5 |
62 |
| Roles of forced nicotine exposure and Comt gene disruption in the development of addiction-related behavioural and neurochemical changes in mice | 9 |
8 |
5 |
4 |
10 |
4 |
8 |
16 |
11 |
7 |
7 |
9 |
98 |
| Screening for marine-derived antivirals | 2 |
3 |
5 |
4 |
6 |
6 |
2 |
7 |
3 |
6 |
5 |
2 |
51 |
| Screening Methods for the Evaluation of Biological Activity in Drug Discovery | 8 |
5 |
3 |
6 |
5 |
12 |
3 |
6 |
17 |
1 |
3 |
1 |
70 |
| Screening of Marine Natural Products and Their Synthetic Derivatives for Antimicrobial and Antiproliferative Properties | 12 |
7 |
7 |
2 |
14 |
5 |
0 |
7 |
1 |
3 |
1 |
1 |
60 |
| Screening Tools for the Identification of Alphavirus Inhibitors | 5 |
8 |
7 |
3 |
12 |
5 |
3 |
9 |
4 |
2 |
2 |
3 |
63 |
| Smart Nanoparticle-Based Platforms for Regulating Tumor Microenvironment and Cancer Immunotherapy | 0 |
71 |
29 |
12 |
6 |
17 |
4 |
4 |
2 |
0 |
5 |
6 |
156 |
| Societal Problem Solving and University Research : Science-Society Interaction and Social Impact in the Educational and Social Sciences | 14 |
4 |
5 |
9 |
3 |
15 |
10 |
8 |
3 |
1 |
2 |
4 |
78 |
| Sol-gel derived silica gel monoliths and microparticles as carrier in controlled drug delivery in tissue administration | 10 |
18 |
9 |
6 |
17 |
3 |
2 |
3 |
4 |
1 |
0 |
1 |
74 |
| Specific Cell – Biomaterial Interactions for In Vivo-Like In Vitro Tissue Models from Human Pluripotent Stem Cells | 14 |
3 |
3 |
7 |
5 |
5 |
8 |
21 |
6 |
2 |
3 |
2 |
79 |
| Stability and analysis of solid-state forms in pharmaceutical powders | 32 |
22 |
31 |
19 |
27 |
24 |
5 |
8 |
11 |
18 |
22 |
14 |
233 |
| Stereochemical and steric control of enzymatic glucuronidation : A rational approach for the design of novel Inhibitors for the human UDP-glucuronosyltransferase 2B7 | 7 |
3 |
8 |
8 |
6 |
10 |
4 |
7 |
2 |
7 |
4 |
4 |
70 |
| Stereoselectivity of the Human UDP-glucuronosyltransferases : Studies on Androgens and Propranolol Glucuronidation | 2 |
10 |
6 |
6 |
11 |
11 |
4 |
6 |
5 |
3 |
4 |
2 |
70 |
| Strategies for Medication Safety : An Organization-Based Approach Focusing on High-Alert Medications and Clinical Pharmacy Services in Helsinki University Hospital | 59 |
85 |
44 |
60 |
40 |
20 |
46 |
96 |
22 |
33 |
55 |
24 |
584 |
| Strategies to enhance efficacy of oncolytic virotherapy | 4 |
1 |
2 |
3 |
16 |
5 |
1 |
5 |
6 |
2 |
1 |
0 |
46 |
| Structure-Activity Relationships of Efflux Transporter Inhibitors | 5 |
9 |
7 |
10 |
9 |
9 |
8 |
3 |
3 |
4 |
3 |
0 |
70 |
| Studies on a Cholesterol-Lowering Microcrystalline Phytosterol suspension in Oil | 11 |
3 |
6 |
7 |
6 |
5 |
3 |
2 |
2 |
2 |
5 |
4 |
56 |
| Studies on aqueous film coating of tablets performed in a side-vented pan coater | 25 |
22 |
41 |
38 |
36 |
50 |
11 |
32 |
13 |
19 |
24 |
11 |
322 |
| Studies on bacterial and host responses in Chlamydia pneumoniae persistent infection models in cell culture | 25 |
26 |
22 |
14 |
22 |
12 |
6 |
6 |
6 |
17 |
11 |
6 |
173 |
| Studies on the developmental and antidepressant-like effects of anesthetics | 4 |
0 |
4 |
3 |
17 |
18 |
7 |
2 |
3 |
2 |
5 |
2 |
67 |
| Studies on Thermosensitive Poly(N-vinylcaprolactam) Based Polymers for Pharmaceutical Applications | 5 |
13 |
5 |
9 |
25 |
6 |
2 |
5 |
2 |
0 |
2 |
2 |
76 |
| SU-8-Based Microchips for Capillary Electrophoresis and Electrospray Ionization Mass Spectrometry | 27 |
6 |
4 |
6 |
7 |
3 |
5 |
1 |
1 |
1 |
3 |
3 |
67 |
| Sulfonation and methylation in silico : Modelling studies on SULT1A3 and COMT | 6 |
3 |
8 |
3 |
9 |
4 |
5 |
4 |
2 |
0 |
4 |
1 |
49 |
| Superficial interactions : the importance of surfaces in the crystallization, stabilization and dissolution of amorphous drugs | 4 |
5 |
7 |
15 |
10 |
8 |
3 |
8 |
7 |
4 |
5 |
3 |
79 |
| Surface Plasmon Resonance-Based Cellular Assays in Pharmaceutical Research : Interpretation of the Label-Free Signals | 3 |
4 |
5 |
13 |
13 |
20 |
6 |
4 |
0 |
2 |
3 |
1 |
74 |
| Synthesis and evaluation of antichlamydial, antileishmanial and antimalarial activity of benzimidazole and benzoxadiazole derivatives | 7 |
7 |
4 |
10 |
5 |
6 |
4 |
2 |
4 |
2 |
3 |
4 |
58 |
| Synthesis and SAR Analysis of GATA4- NKX2-5 Interaction Inhibitors with Antihypertrophic Activity | 2 |
1 |
4 |
3 |
15 |
7 |
7 |
3 |
2 |
6 |
4 |
6 |
60 |
| Synthesis of Abietane-Type Diterpenoids with Anticancer Activity | 19 |
11 |
5 |
15 |
11 |
7 |
7 |
3 |
10 |
5 |
3 |
5 |
101 |
| Synthesis of Antimicrobial Surfaces and Compounds to Target Resistant Staphylococcus aureus | 6 |
6 |
4 |
5 |
11 |
5 |
10 |
8 |
5 |
9 |
6 |
4 |
79 |
| Synthesis of Azulene-Based Compounds for Targeting Orexin Receptors | 22 |
6 |
13 |
7 |
22 |
17 |
5 |
9 |
11 |
5 |
5 |
4 |
126 |
| Synthesis of betulin derivatives against intracellular pathogens | 16 |
13 |
6 |
6 |
14 |
5 |
2 |
4 |
8 |
1 |
2 |
3 |
80 |
| Synthesis of betulin derivatives with new bioactivities | 11 |
13 |
13 |
13 |
10 |
4 |
2 |
3 |
2 |
0 |
2 |
1 |
74 |
| Synthesis of Nitrogen-Containing Five-Membered Heterocycles : 1,3-Dipolar Cycloadditions, Solid-Phase Techniques, and Parallel Methods | 15 |
13 |
11 |
9 |
17 |
13 |
2 |
3 |
5 |
73 |
7 |
6 |
174 |
| Synthesis of Six-Membered Rings and Inhibitors of Protein Kinases | 33 |
7 |
16 |
5 |
31 |
50 |
47 |
9 |
8 |
5 |
9 |
11 |
231 |
| Terveyspalveluita vai myyntityötä : Apteekkien toiminnan strateginen kehittäminen muuttuvassa toimintaympäristössä | 17 |
71 |
30 |
45 |
29 |
14 |
3 |
9 |
23 |
21 |
37 |
21 |
320 |
| The Caco-2 cell line in studies of drug metabolism and efflux | 8 |
10 |
7 |
12 |
11 |
18 |
10 |
5 |
3 |
5 |
3 |
3 |
95 |
| The DAG-responsive C1 domain as a drug target : structure-activity and in vitro pharmacology of isophthalate derivatives | 6 |
3 |
5 |
3 |
6 |
3 |
3 |
4 |
10 |
11 |
6 |
5 |
65 |
| The Economic Impact of Fluoroquinolone-related Adverse Reactions in Finland : Studies on Costs, Health Service Use and Mortality | 12 |
14 |
11 |
11 |
13 |
2 |
4 |
3 |
3 |
9 |
4 |
5 |
91 |
| The effect of prolyl oligopeptidase inhibition on protein aggregation and oxidative stress in the models of neurodegenerative diseases | 0 |
0 |
0 |
156 |
22 |
11 |
5 |
8 |
4 |
15 |
1 |
2 |
224 |
| The effect of systemically and locally administered clodronate on bone quality | 20 |
7 |
9 |
3 |
4 |
5 |
1 |
4 |
4 |
2 |
2 |
1 |
62 |
| The effects of anticholinesterases and β-amyloid pathology on neurotrophin signaling in the mouse brain | 3 |
1 |
2 |
5 |
5 |
3 |
4 |
1 |
5 |
3 |
3 |
3 |
38 |
| The Effects of Nicotine on the Regulation of Neuronal Alpha7 Nicotinic Acetylcholine Receptors and Intracellular Signalling Pathways | 2 |
7 |
3 |
3 |
7 |
3 |
1 |
1 |
1 |
1 |
1 |
1 |
31 |
| The Effects of Prolyl Oligopeptidase Inhibition in α-Synuclein Based Mouse Models of Parkinson's Disease | 5 |
8 |
6 |
3 |
9 |
4 |
0 |
1 |
6 |
3 |
1 |
3 |
49 |
| The effects of psychostimulant drugs on brain dopaminergic and serotonergic neuronal systems : the role of 5-HT3 receptors | 2 |
3 |
5 |
5 |
6 |
3 |
4 |
2 |
2 |
3 |
0 |
1 |
36 |
| The influence of soluble components and culture conditions on hepatic differentiation of human pluripotent stem cells | 7 |
5 |
7 |
2 |
6 |
6 |
6 |
4 |
5 |
0 |
3 |
0 |
51 |
| The interfacial behaviour of sorbitan surfactant monolayers and the bulk properties of these surfactants as a function of temperature | 22 |
10 |
7 |
14 |
15 |
6 |
4 |
5 |
5 |
7 |
8 |
0 |
103 |
| The role and therapeutic effect of CDNF in animal models of neurodegenerative diseases | 0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
5 |
5 |
| The role of GDNF and its receptor GFRa1 in neuronal development and function | 9 |
7 |
11 |
13 |
7 |
12 |
3 |
10 |
10 |
4 |
2 |
7 |
95 |
| The role of the carrier and the endocytic pathway in non-viral gene delivery | 7 |
0 |
8 |
7 |
7 |
3 |
1 |
0 |
1 |
110 |
122 |
2 |
268 |
| The roughness and imaging characterisation of different pharmaceutical surfaces | 7 |
7 |
10 |
26 |
11 |
4 |
3 |
4 |
13 |
0 |
1 |
1 |
87 |
| The search for biological activity in Finnish plant extracts containing phenolic compounds | 12 |
15 |
5 |
8 |
5 |
10 |
3 |
8 |
11 |
2 |
5 |
6 |
90 |
| The use of molecular dynamics simulation for the study of polymeric and lipid based drug delivery systems | 43 |
22 |
21 |
8 |
23 |
18 |
2 |
5 |
3 |
4 |
9 |
2 |
160 |
| The value of hard gelatin capsules as a rectal dosage form in man using ibuprofen and metoclopramide hydrochloride as model drugs | 11 |
6 |
5 |
4 |
5 |
6 |
2 |
15 |
25 |
31 |
10 |
6 |
126 |
| Therapeutic proteins and their use in posterior eye segment diseases | 10 |
12 |
10 |
8 |
13 |
9 |
5 |
2 |
3 |
4 |
14 |
10 |
100 |
| Thin-Layer Chromatography with Ultraviolet and Mass Spectrometric Detection : From Preparative-Layer to Miniaturized Ultra-Thin-Layer Technique | 2 |
5 |
6 |
3 |
9 |
7 |
4 |
4 |
4 |
17 |
21 |
16 |
98 |
| Thiol-ene based microfluidic devices for bioanalysis | 22 |
22 |
8 |
4 |
16 |
18 |
34 |
31 |
9 |
10 |
9 |
9 |
192 |
| Toward accurate high-throughput physicochemical profiling using image-based single-particle analysis | 4 |
2 |
11 |
1 |
6 |
6 |
8 |
5 |
6 |
5 |
0 |
5 |
59 |
| Towards real-time understanding of processes in pharmaceutical powder technology | 12 |
4 |
8 |
10 |
2 |
0 |
2 |
1 |
5 |
0 |
12 |
7 |
63 |
| Towards Understanding Powder Behavior Via Simulation | 6 |
0 |
3 |
14 |
4 |
6 |
1 |
1 |
7 |
1 |
13 |
10 |
66 |
| Transcription Factors ∆FosB and CREB in Drug Addiction : Studies in Models of Alcohol Preference and Chronic Nicotine Exposure | 17 |
15 |
10 |
16 |
15 |
9 |
6 |
5 |
22 |
7 |
11 |
16 |
149 |
| Transdermal Iontophoresis : Delivery Control by Ion-Exchange Fibers and Nanocarriers | 12 |
14 |
14 |
11 |
9 |
4 |
8 |
6 |
6 |
12 |
8 |
4 |
108 |
| UDP-glucuronosyltransferases in sickness and health : Studies on bilirubin and steroid glucuronidation | 7 |
10 |
9 |
6 |
20 |
16 |
2 |
0 |
1 |
5 |
4 |
4 |
84 |
| UGTs and glucuronidation analyses in Caco-2 cells, human microsomes and recombinant enzymes | 0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Ultrasound-assisted surface engineering of pharmaceutical powders | 9 |
6 |
4 |
11 |
8 |
9 |
5 |
6 |
4 |
3 |
14 |
6 |
85 |
| Underlying Mechanisms of Prolyl Oligopeptidase Inhibition, Deletion, and Restoration on the α-Synuclein Aggregation Process | 4 |
6 |
11 |
13 |
11 |
4 |
2 |
4 |
2 |
0 |
4 |
1 |
62 |
| Understanding Human Drug Conjugating Enzymes : Regio- and Stereoselectivity in Sulfotransferase 1A3 and the UDP-Glucuronosyltransferases | 3 |
2 |
2 |
6 |
1 |
4 |
2 |
0 |
5 |
2 |
6 |
2 |
35 |
| Understanding solid-state transformations during dehydration : new insights using vibrational spectroscopy and multivariate modelling | 19 |
5 |
2 |
9 |
5 |
7 |
9 |
5 |
4 |
3 |
2 |
1 |
71 |
| Upregulation and Functionality of Neuronal Nicotinic Acetylcholine Receptors | 5 |
1 |
2 |
4 |
6 |
5 |
2 |
2 |
7 |
2 |
1 |
3 |
40 |
| Use of Antimicrobials in a Tertiary Children’s Hospital | 13 |
11 |
6 |
3 |
14 |
6 |
0 |
0 |
1 |
0 |
3 |
0 |
57 |
| Use of Mercury Porosimetry and Nitrogen Adsorption in Characterisation of the Pore Structure of Mannitol and Microcrystalline Cellulose Powders, Granules and Tablets | 27 |
19 |
17 |
23 |
18 |
8 |
5 |
3 |
7 |
3 |
3 |
4 |
137 |
| Vangittu tieto vapaaksi : asiantuntijuus ja sen kehittyminen farmasiassa | 4 |
10 |
6 |
7 |
14 |
8 |
11 |
8 |
1 |
11 |
11 |
5 |
96 |
| Voimaantumiseen pohjautuva tyypin 2 diabeteksen omahoidon tuki apteekissa : Esimerkkinä Mäntyharjun Havu-apteekki | 23 |
17 |
12 |
27 |
21 |
10 |
7 |
9 |
34 |
46 |
17 |
15 |
238 |
| Why patients do not take medication as prescribed: The complexity of medication adherence as a phenomenon | 56 |
61 |
59 |
23 |
39 |
16 |
3 |
17 |
30 |
17 |
24 |
26 |
371 |